Management of Melanoma Brain Metastasis
In the past decades, local therapies including surgery, whole-brain radiation therapy, and stereotactic radiosurgery were considered the pillar of metastatic brain metastasis (MBM) management, although their benefit in terms of overall survival was never demonstrated. Advances in understanding the biology and molecular pathways implicated in melanoma biology and consecutive improvements in metastatic melanoma treatment using anti-BRAF-based targeted therapies for BRAFV600-mutant melanoma as well as immune checkpoint immunotherapy have generated considerable interest in evaluating these novel systemic therapies in treating MBM (Table 22.1).
- 9.Di Giacomo AM, Annesi D, Ascierto PA, Calabrò L, Chiarion-Sileni V, Danielli R, et al. A randomized, phase III study of fotemustine versus the combination of fotemustine and ipilimumab or the combination of ipilimumab and nivolumab in patients with metastatic melanoma with brain metastasis: the NIBIT-M2 trial. J Clin Oncol. 2015;33.(suppl:9090.CrossRefGoogle Scholar
- 10.Long GV, Atkinson V, Menzies AM, Lo S, Guminski AD, Brown MP, et al. A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): The Anti-PD1 Brain Collaboration (ABC). J Clin Oncol. 2017;35.(Suppl:9508.CrossRefGoogle Scholar
- 18.Hodi FS, Ballinger M, Lyons B, Soria JC, Nishino M, Tabernero J, et al. Immune-modified response evaluation criteria in solid tumors (imRECIST): refining guidelines to assess the clinical benefit of cancer immunotherapy. J Clin Oncol. 2018:JCO2017751644.. [Epub ahead of print].Google Scholar